Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Next-Generation Sequencing to Assess the Impact of Low Dose Melphalan on Residual Disease before High-Dose Melphalan and Stem Cell Transplant in Multiple Myeloma

Ehsan Malek, Mary Hislop, Leland Metheny, III, Molly Gallogly, Marcos J.G. de Lima, Farhad Sanati, Hannah Elizabeth Schmikla, Brett Glotzbecker, James Driscoll

Blood (2021) 138 (Supplement 1): 4933.

https://doi.org/10.1182/blood-2021-148220

Published: 2021

Journal Articles

Patient Selection Bias Limits the Real World Efficacy of Randomized Clinical Trials in Multiple Myeloma

Augusta Eduafo, DO, Leland Metheny, III, MD, James Driscoll, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Molly M Gallogly, MDPhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139856

Published: 2020

Journal Articles

Health Care Burden of Monogammopathy of Renal Significance

Jeries Kort, MD, Paolo F Caimi, MD, Pingfu Fu, PhD, Shufen Cao, James Driscoll, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 34–36.

https://doi.org/10.1182/blood-2020-139740

Published: 2020

Journal Articles

Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Ehsan Malek, MD, Jeries Kort, MD, Gi-Ming Wang, PhD, Paolo F Caimi, MD, Kirsten M Boughan, DO, Stanton L. Gerson, MD, Brenda W. Cooper, MD, Molly M Gallogly, MDPhD, Benjamin K. Tomlinson, MD, Marcos de Lima, MD, Curtis Tatsuoka, PhD, James Driscoll

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-139733

Published: 2020

Journal Articles

Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

Ehsan Malek, MD, Petra Martin, Paolo F Caimi, MD, Benjamin K. Tomlinson, MD, Michael Caldwell, Gayathri Ravi, MD, Sowjanya Vuyyala, MD, Hannah Schmikla, RN, Robert Fox, Marcos de Lima, MD, Navid Sadri, MD, James Driscoll, MD PhD

Blood (2019) 134 (Supplement_1): 515.

https://doi.org/10.1182/blood-2019-127335

Published: 2019

Journal Articles

Risk of Progression in Patients with Smoldering Myeloma

Fahrettin Covut, MD, Kamal Chamoun, MD, Leland Metheny, III, MD, Kirsten M Boughan, DO, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 1892.

https://doi.org/10.1182/blood-2019-127677

Published: 2019

Journal Articles

Meta-Analyses of Clinical Trials Comparing the Progression Free Survival and Adverse Events in Treated Versus Observed Patients with Smoldering and Indolent Multiple Myeloma

Fahrettin Covut, MD, Tariq Zuheir Kewan, MD, Apoorva Anandan, MD, Folashade Otegbeye, MBBChir,MPH, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 2196.

https://doi.org/10.1182/blood-2019-125954

Published: 2019

Journal Articles

Serum Electrolyte Dynamics in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Apoorva Anandan, MD, Pingfu Fu, Merle Kolk, Nicole Ferrari, Arash Rashidi, MD, Melissa Copley, PharmD, James Driscoll, MD PhD, Paolo Caimi, MD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 5646.

https://doi.org/10.1182/blood-2019-122057

Published: 2019

Journal Articles

Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-β Signaling Pathway

Ehsan Malek, MD, Sunjin Hwang, MD, Marcos de Lima, MD, Paolo Caimi, MD, Molly M Gallogly, MD PhD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Brenda Cooper, MD, James Driscoll, MD PhD, John Letterio, MD

Blood (2019) 134 (Supplement_1): 3232.

https://doi.org/10.1182/blood-2019-126728

Published: 2019

Journal Articles

Impact of Previous Cancer Therapy on Outcome of Patients with Multiple Myeloma or Smoldering Disease

Fahrettin Covut, MD, Gayathri Ravi, MD, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 3174.

https://doi.org/10.1182/blood-2019-126059

Published: 2019

Journal Articles

Factors Influencing Incidence of Supraventricular Arrhythmias during and after Autologous Stem Cell Transplant in Multiple Myeloma

Megan Sturdy, MD, Rebecca Ye, BA, Trevor L Jenkins, MD, James Driscoll, MD PhD, Paolo Caimi, MD, Leland Metheny, MD, Rachel Zebrowski, RN, Nicole Ferrari, Merle Kolk, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2018) 132 (Supplement 1): 4834.

https://doi.org/10.1182/blood-2018-99-113828

Published: 2018

Journal Articles

Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant

Petra Martin, MD, Rebecca Ye, BA, Merle Kolk, Nicole Ferrari, Paolo Caimi, MD, Leland Metheny, MD, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2018) 132 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2018-99-113833

Published: 2018

Journal Articles

Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide

Ehsan Malek, MD, Byung-Gyu Kim, PhD DVM, Jason Valent, MD, James Driscoll, MD PhD, Paolo Caimi, MD, Seong-Jin Kim, PhD, Marcos de Lima, MD, John Letterio, MD

Blood (2018) 132 (Supplement 1): 1962.

https://doi.org/10.1182/blood-2018-99-112449

Published: 2018

Journal Articles

Vactosertib, a TGF-ß Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors

Byung-Gyu Kim, PhD DVM, Sung Hee Choi, PhD, George Luo, Olga Sergeeva, PhD, Zhenghong Lee, PhD, James Driscoll, MD PhD, Marcos de Lima, MD, Rose Beck, MD PhD, Seong-Jin Kim, PhD, John Letterio, MD, Ehsan Malek, MD

Blood (2018) 132 (Supplement 1): 1918.

https://doi.org/10.1182/blood-2018-99-117852

Published: 2018

Journal Articles

Eosinophils Upregulate PD-L1 and PD-L2 Expression to Enhance the Immunosuppressive Microenvironment in Multiple Myeloma

James Driscoll, MD PhD, Irim Aslam, Ehsan Malek, MD

Blood (2017) 130 (Supplement 1): 4417.

https://doi.org/10.1182/blood.V130.Suppl_1.4417.4417

Published: 2017

Journal Articles

Defining a Bone Marrow Immune Signature Associated with Immunoglobulin Isotype Switching after Autologous Stem Cell Transplant

Rebecca Ye, Sirisha Kundrapu, Stanton L. Gerson, MD, Rose Beck, MD PhD, James Driscoll, MD PhD, Suchitra Sundaram, MBBS, Byung-Gyu Kim, PhD DVM, Willem vanHeeckeren, Marcos De Lima, MD, Ehsan Malek, MD

Blood (2017) 130 (Supplement 1): 3038.

https://doi.org/10.1182/blood.V130.Suppl_1.3038.3038

Published: 2017

Journal Articles

Single-Cell Transcriptomics of Human Plasma Cells from HLA-Sensitized Patients Reveals Population Heterogeneity and Drug Resistance Adaptations

James Driscoll, MD PhD, Simon Tremblay, PharmD, Nathan Salomonis, PhD, Harinder Singh, PhD, E. Steve Woodle, MD

Blood (2017) 130 (Supplement 1): 1901.

https://doi.org/10.1182/blood.V130.Suppl_1.1901.1901

Published: 2017

Journal Articles

Genomic and Biochemical Proteasomal Adaptations in Carfilzomib-Resistant Plasma Cells That Limit HLA-Desensitization in Transplantation Candidates

James Driscoll, MD PhD, Simon Tremblay, PharmD, Nupur Dasgupta, PhD, Bruce Aronow, PhD, Harinder Singh, PhD, E. Steve Woodle, MD

Blood (2017) 130 (Supplement 1): 5448.

https://doi.org/10.1182/blood.V130.Suppl_1.5448.5448

Published: 2017

Journal Articles

Cullin-1 Controls The Clinical and Cellular response to Bortezomib Through NF-Kb Pathway Activation In Myeloma

James Driscoll, MD, PhD, Elias J. Anaissie, MD, Sajjeev Jagannathan, BS

Blood (2013) 122 (21): 4445.

https://doi.org/10.1182/blood.V122.21.4445.4445

Published: 2013

Journal Articles

Autophagy Is Uncoupled From ATG5-Dependent Apoptosis in Cells Resistant To Proteasome Inhibition

James Driscoll, MD, PhD, Elias J. Anaissie, MD, Sajjeev Jagannathan, BS

Blood (2013) 122 (21): 4448.

https://doi.org/10.1182/blood.V122.21.4448.4448

Published: 2013

NARROW

Next-Generation Sequencing to Assess the Impact of Low Dose Melphalan on Residual Disease before High-Dose Melphalan and Stem Cell Transplant in Multiple Myeloma

Patient Selection Bias Limits the Real World Efficacy of Randomized Clinical Trials in Multiple Myeloma

Health Care Burden of Monogammopathy of Renal Significance

Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

Risk of Progression in Patients with Smoldering Myeloma

Meta-Analyses of Clinical Trials Comparing the Progression Free Survival and Adverse Events in Treated Versus Observed Patients with Smoldering and Indolent Multiple Myeloma

Serum Electrolyte Dynamics in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-β Signaling Pathway

Impact of Previous Cancer Therapy on Outcome of Patients with Multiple Myeloma or Smoldering Disease

Factors Influencing Incidence of Supraventricular Arrhythmias during and after Autologous Stem Cell Transplant in Multiple Myeloma

Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant

Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide

Vactosertib, a TGF-ß Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors

Eosinophils Upregulate PD-L1 and PD-L2 Expression to Enhance the Immunosuppressive Microenvironment in Multiple Myeloma

Defining a Bone Marrow Immune Signature Associated with Immunoglobulin Isotype Switching after Autologous Stem Cell Transplant

Single-Cell Transcriptomics of Human Plasma Cells from HLA-Sensitized Patients Reveals Population Heterogeneity and Drug Resistance Adaptations

Genomic and Biochemical Proteasomal Adaptations in Carfilzomib-Resistant Plasma Cells That Limit HLA-Desensitization in Transplantation Candidates

Cullin-1 Controls The Clinical and Cellular response to Bortezomib Through NF-Kb Pathway Activation In Myeloma

Autophagy Is Uncoupled From ATG5-Dependent Apoptosis in Cells Resistant To Proteasome Inhibition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only